Thomas L Richie Selected Research

Thomas L Richie Research Topics

Disease

84	Malaria 03/2022 - 01/2002
44	Infections 03/2022 - 08/2003
13	Parasitemia 02/2022 - 10/2007
10	Bites and Stings (Sting) 01/2021 - 08/2012
7	Falciparum Malaria (Plasmodium falciparum Malaria) 04/2019 - 03/2002
4	Communicable Diseases (Infectious Diseases) 01/2020 - 02/2002
2	Tuberculosis (Tuberculoses) 12/2017 - 08/2013
2	Fever (Fevers) 01/2017 - 07/2003
2	Vivax Malaria 02/2016 - 04/2006
2	Parasitic Diseases (Parasitic Disease) 12/2015 - 11/2015
1	Lymphadenopathy 11/2020
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 11/2020
1	Sickle Cell Trait 01/2018
1	Headache (Headaches) 01/2017
1	Fatigue 01/2017
1	Myalgia 01/2017
1	Body Weight (Weight, Body) 04/2010
1	Neoplasms (Cancer) 05/2004
1	Acquired Immunodeficiency Syndrome (AIDS) 05/2004
1	Pruritus (Itching) 07/2003
1	Tinnitus 07/2003
1	Heartburn (Pyrosis) 07/2003
1	Exanthema (Rash) 07/2003
1	Hearing Loss (Hearing Impairment) 07/2003
1	Paresthesia (Dysesthesia) 07/2003

Drug/Important Bio-Agent (IBA)

66	VaccinesIBA 02/2022 - 01/2002
26	1- acetyl- 1,2,3,3a,8,8a- hexahydro- 8a- hydroxy- 5- methoxypyrrolo(2,3- b)indole (CHMI)IBA 03/2022 - 08/2012
19	AntigensIBA 02/2022 - 06/2004
19	Malaria VaccinesIBA 01/2022 - 02/2007
11	Proteins (Proteins, Gene)FDA Link 02/2022 - 08/2003
11	AntibodiesIBA 02/2022 - 08/2003
10	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 03/2002
5	EpitopesIBA 01/2021 - 06/2004
5	Chloroquine (Aralen)FDA LinkGeneric 01/2021 - 04/2006
5	DNA VaccinesIBA 11/2012 - 03/2002
4	Antimalarials (Antimalarial Agents)IBA 01/2021 - 02/2011
3	Merozoite Surface Protein 1 (MSA1)IBA 02/2022 - 10/2008
3	Peptides (Polypeptides)IBA 01/2021 - 08/2003
3	Indicators and Reagents (Reagents)IBA 01/2021 - 11/2013
3	A-Form DNA (A-DNA)IBA 01/2021 - 01/2013
3	Pharmaceutical PreparationsIBA 10/2020 - 06/2010
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 11/2009
2	Subunit VaccinesIBA 01/2020 - 01/2013
2	Mefloquine (Lariam)FDA LinkGeneric 01/2017 - 04/2006
2	vaxfectinIBA 04/2010 - 03/2006
2	LipidsIBA 04/2010 - 03/2006
2	ImmunosorbentsIBA 10/2009 - 10/2008
2	EnzymesIBA 10/2009 - 10/2008
2	Doxycycline (Periostat)FDA LinkGeneric 12/2008 - 07/2003
2	Interferon-gamma (Interferon, gamma)IBA 10/2007 - 05/2005
2	Immunoglobulin G (IgG)IBA 06/2004 - 08/2003
2	Recombinant ProteinsIBA 05/2004 - 04/2004
1	Ribosomal DNA (rDNA)IBA 03/2022
1	ThrombospondinsIBA 01/2021
1	Interleukin-2 (IL2)IBA 01/2021
1	Pyrimethamine (Daraprim)FDA Link 01/2021
1	18S Ribosomal RNAIBA 01/2019
1	N-acetyltalosaminuronic acid (NAT)IBA 01/2019
1	Hemoglobins (Hemoglobin)IBA 01/2018
1	Complement System Proteins (Complement)IBA 01/2018
1	Adenovirus VaccinesIBA 01/2017
1	HLA-DR4 Antigen (HLA DR4 Antigen)IBA 01/2014
1	Histocompatibility Antigens Class IIIBA 01/2014
1	HLA-DQ8 antigenIBA 01/2014
1	HLA-DQ6 antigenIBA 01/2014
1	HLA-DR3 Antigen (HLA DR3 Antigen)IBA 01/2014
1	HLA-DR Antigens (HLA-DR)IBA 10/2013
1	AIDS VaccinesIBA 08/2013
1	Galactosylceramides (Galactocerebrosides)IBA 01/2013
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 11/2012
1	Synthetic Vaccines (Recombinant Vaccines)IBA 01/2010
1	Surface Antigens (Surface Antigen)IBA 02/2007
1	Glycosylphosphatidylinositols (Glycosyl-Phosphatidylinositol)IBA 07/2003
1	Azithromycin (Zithromax)FDA LinkGeneric 07/2003

Therapy/Procedure

5	Chemoprevention 01/2021 - 10/2013
3	Injections 01/2021 - 10/2007
2	Mass Drug Administration 01/2017 - 12/2015
1	Intravenous Injections 01/2017
1	Jet Injections 11/2012